youtube_live
Q3 2026 earnings • released • EPS beat +11,38% • Revenue beat +7,33%
See resultschevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
29,41 USD
arrow_upward
+4,03%(+1,14) 1D
28,97 USD
arrow_downward
-1,50% (-0,44)bedtimeAfter hours
Closed: 6-ноя., 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
28,99 USD
High
29,80 USD
Low
28,46 USD
Mkt. cap
1,76 млд
Avg. vol.
1,28 млн
Volume
1,28 млн
52-wk high
45,99 USD
52-wk low
22,24 USD
EPS
-7,01 USD
Beta
0,66
Shares outstanding
59,70 млн
No. of employees
540
Open
28,99 USD
High
29,80 USD
Low
28,46 USD
Mkt. cap
1,76 млд
Avg. vol.
1,28 млн
Volume
1,28 млн
52-wk high
45,99 USD
52-wk low
22,24 USD
EPS
-7,01 USD
Beta
0,66
Shares outstanding
59,70 млн
No. of employees
540
News stories
From web sources and news partners
TradingView
·
1 күн мурун
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call
Benzinga
·
1 күн мурун
Agios Pharmaceuticals Q3 2026 Earnings Call Transcript
GuruFocus
·
2 күн мурун
Agios Pharmaceuticals Reports Q3 2026 Revenue of $55.4 Million,
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc